In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1588-1593

  Sato, Takafumi ^a,b   Tateda, Kazuhiro ^a   Kimura, Soichiro ^a   Iwata, Morihiro ^c   Ishii, Yoshikazu ^a   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; METHYLTRANSFERASE; MODITHROMYCIN; PROTEIN ERM; PROTEIN MEFA; PROTEIN MEFB; PROTEIN MEFE; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BROTH DILUTION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; LEGIONELLA LONGBEACHAE; LEGIONELLA PNEUMOPHILA; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT EXAMINATION; RIBOSOME; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TATLOCKIA MICDADEI;

ANTI-BACTERIAL AGENTS; BRIDGED COMPOUNDS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; KETOLIDES; LEGIONELLA; LEGIONELLA LONGBEACHAE; LEGIONELLA PNEUMOPHILA; MACROLIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 79953196140     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01469-10     Document Type: Article

References (29)

1. Al-Lahham, A., P. C. Appelbaum, M. van der Linden, and R. R. Reinert. 2006. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe. Antimicrob. Agents Chemother. 50:3897-3900.
2. Atkinson, M., M. Yanney, T. Stephenson, and A. Smyth. 2007. Effective treatment strategies for paediatric community-acquired pneumonia. Expert Opin. Pharmacother. 8:1091-1101.
3. Baquero, F., G. Baquero-Artigao, R. Cantón, and C. García-Rey. 2002. Antibiotic consumption and resistance selection in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50(Suppl. 2):S27-S37.
4. Bergman, M., et al. 2006. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:3646-3650.
5. Čižman, M., M. Pokorn, K. Seme, A. Oražem, and M. Paragi. 2001. The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens. J. Antimicrob. Chemother. 47:475-477.
6. Čižman, M., M. Pokorn, K. Seme, M. Paragi, and A. Oražem. 1999. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur. J. Clin. Microbiol. Infect. Dis. 18:522-524.
7. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing, 16th informational supplement M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Douthwaite, S., J. Jalava, and L. Jakobsen. 2005. Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. Mol. Microbiol. 58:613-622.
10. Farrell, D. J., et al. 2005. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg. Infect. Dis. 11:851-858.
11. Farrell, D. J., C. Couturier, and W. Hryniewicz. 2008. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004). Int. J. Antimicrob. Agents 31:245-249.
12. Felmingham, D., R. Cantón, and S. G. Jenkins. 2007. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J. Infect. 55:111-118.
13. Green, N. M., et al. 2005. Genetic diversity among type emm28 group A Streptococcus strains causing invasive infections and pharyngitis. J. Clin. Microbiol. 43:4083-4091.
14. Inoue, M., et al. 2008. Antimicrobial susceptibility of respiratory tract pathogens in Japan during PROTEKT years 1-5 (1999-2004). Microb. Drug Resist. 14:109-117.
15. Kataja, J., P. Huovinen, M. Skurnik, the Finnish Study Group for Antimicrobial Resistance, and H. Seppälä. 1999. Erythromycin resistance genes in group A streptococci in Finland. Antimicrob. Agents Chemother. 43:48-52.
16. Klugman, K. P. 2007. Clinical impact of antibiotic resistance in respiratory tract infections. Int. J. Antimicrob. Agents 29(Suppl. 1):S6-S10.
17. Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34:482-492.
18. Lina, G., et al. 1999. Distribution of genes encoding resistance to macrolides, lincosamides and streptogramins among staphylococci. Antimicrob. Agents Chemother. 43:1062-1066.
19. Low, D. E. 2008. Treatment of community-acquired pneumonia. CMAJ 179:1245-1246.
20. Ma, Z., et al. 2001. Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. J. Med. Chem. 44:4137-4156.
21. Martineau, F., et al. 2000. Multiplex PCR assays for the detection of clinically relevant antibiotic resistance genes in staphylococci isolated from patients infected after cardiac surgery. J. Antimicrob. Chemother. 46:527-534.
22. Miyazaki, S., et al. 2001. In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections. Antimicrob. Agents Chemother. 45:203-207.
23. Nawaz, M. S., S. A. Khan, A. A. Khan, F. M. Khambaty, and C. E. Cerniglia. 2000. Comparative molecular analysis of erythromycin-resistance determinants in staphylococcal isolates of poultry and human origin. Mol. Cell. Probes 14:311-319.
24. Reynolds, E. D., and J. H. Cove. 2005. Resistance to telithromycin is conferred by msr(A), msrC and msr(D) in Staphylococcus aureus. J. Antimicrob. Chemother. 56:1179-1182.
25. Sato, T., K. Tateda, S. Kimura, Y. Ishii, and K. Yamaguchi. 2011. In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila. Antimicrob. Agents Chemother. 55:1594-1597.
26. Stout, J. E., K. Sens, S. Mietzner, A. Obman, and V. L. Yu. 2005. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int. J. Antimicrob. Agents 25:302-307.
27. Syrogiannopoulos, G. A., et al. 2003. Antimicrobial susceptibility and macrolide resistance inducibility of Streptococcus pneumoniae carrying erm(A), erm(B), or mef(A). Antimicrob. Agents Chemother. 47:2699-2702. (Pubitemid 36919486)
28. Van Bambeke, F., J. M. Harms, Y. Van Laethem, and P. M. Tulkens. 2008. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin. Pharmacother. 9:267-283.
29. Wolter, N., A. M. Smith, D. E. Low, and K. P. Klugman. 2007. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:1092-1095.